GlassScriptPhysician profile
Sajjad Haider
NPI 1396091104
$5,862.29
in general payments reported to CMS, 2019-2025
45 companies · $1,637 in 2025
The $1,637 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $333 · 2020: $313 · 2021: $478 · 2022: $1,055 · 2023: $1,102 · 2024: $944 · 2025: $1,637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,629 · Travel and Lodging: $974 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,628.99 |
| Travel and Lodging | $974.09 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,083.54 | 2020-2025 | Versacross Connect Laac Access Solution, Bodyguardian |
| Abiomed | $786.31 | 2021-2025 | Impella |
| Janssen Pharmaceuticals, INC | $412.52 | 2019-2024 | Xarelto |
| Abbott Laboratories | $361.79 | 2021-2025 | Jot Dx, Thoratec Heartmate 3 Lvas Implant Kit |
| Amgen INC. | $343.90 | 2021-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $329.61 | 2019-2025 | Lifevest |
| Pfizer INC. | $259.89 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $213.96 | 2022-2024 | Opsumit, Uptravi |
| Novartis Pharmaceuticals Corporation | $189.67 | 2019-2025 | |
| Shockwave Medical, INC | $189.32 | 2021-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Philips North America LLC | $183.38 | 2020-2024 | (Ck4) Mcot |
| E.R. Squibb & Sons, L.L.C. | $167.98 | 2019-2025 | Camzyos, Eliquis |
| Grifols USA, LLC | $157.36 | 2020-2023 | Prolastin-C Liquid |
| Penumbra, INC. | $149.97 | 2024 | Indigo System |
| Astrazeneca Pharmaceuticals LP | $123.15 | 2019-2025 | Farxiga |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sajjad Haider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.